Upadacitinib
Upadacitinib is an orally administered, once-daily selective Janus kinase 1 (JAK1) inhibitor, formulated as an extended-release tablet and classified under ATC code L04.
Upadacitinib is an orally administered, once-daily selective Janus kinase 1 (JAK1) inhibitor, formulated as an extended-release tablet and classified under ATC code L04. JAK enzymes work in pairs beneath cytokine receptors, and which pair a drug blocks determines both what it treats and what it costs the patient: JAK1 partners in the receptors for Interleukin-6 (IL-6), the common gamma-chain cytokine IL-4 and IL-13, and the interferons, whereas JAK2 carries erythropoietin and thrombopoietin signaling. Preferential inhibition of JAK1 is therefore intended to suppress inflammatory signaling while sparing the haematopoietic effects that follow from blocking JAK2 — selectivity that is relative rather than absolute, and narrows as the dose rises. Not every inflammatory cytokine runs through this system: IL-17A signals through its own receptor and the ACT1–NF-κB/MAPK route, outside JAK/STAT entirely.
The drug is approved across a wide range of immune-mediated inflammatory diseases, including rheumatoid and psoriatic arthritis, axial spondyloarthritis, atopic dermatitis in adults and adolescents, ulcerative colitis, Crohn's disease (CD) and giant cell arteritis — a breadth that follows from blocking a signaling node shared by many cytokines rather than a single mediator. Compared with a biologic such as dupilumab, which neutralizes the IL-4 receptor alpha chain, upadacitinib suppresses several cytokine axes at once through an oral agent, which can help in refractory or overlapping phenotypes; compared with the earlier, less selective tofacitinib and baricitinib, its narrower profile is the intended advance.
Breadth of coverage is also the source of risk. Upadacitinib carries the class boxed warnings extrapolated from tofacitinib's cardiovascular outcome trial — serious infection, major adverse cardiovascular events, malignancy and thrombosis — together with herpes zoster reactivation, and laboratory monitoring of blood counts, lipids and liver enzymes is routine. Whether JAK1 selectivity translates into a genuinely better safety profile than first-generation agents remains an open question rather than an established one.
Where the papers sit
21 papers from the last 6 months study upadacitinib directly · updated from PubMed 13 Nov 2026
Study type 5 clinical trials · 5 observational · 2 human data · 9 unclassified
Themes 4 themes · 1 paradigm shift · 1 new direction
-
Atopic Dermatitis Disease Control
Long-term control of moderate-to-severe atopic dermatitis is being compared between upadacitinib and dupilumab in routine care. Cumulative disease control, EASI response trajectories, minimal disease activity and quality of life recur as practical endpoints, with oral microbiome changes adding a biological correlate. Both treatments support sustained benefit, while structured benefit–risk analyses frame their trade-offs rather than declaring one universal winner. Correlations between patient-reported control tools and minimal disease activity remain central to judging durable response.
7 papers · 33.3%
-
Crohn Disease Treatment Outcomes
Crohn disease management is moving toward real-world assessment of upadacitinib in difficult-to-treat patients beyond induction. Multicentre cohorts track clinical remission, Harvey Bradshaw Index responses, adverse events and durability through 24 weeks to 18 months. The recurring question is whether trial efficacy and safety persist in routine care, including unusual events such as semen discoloration. Smaller peripheral reports extend evaluation to SAPHO syndrome, while formulation work addresses bioequivalence rather than disease control.
6 papers · 28.6%
-
Ulcerative Colitis Advanced Therapy
Advanced therapy selection in ulcerative colitis is shifting toward comparative real-world effectiveness rather than isolated trial efficacy. Upadacitinib is reported with a low risk of treatment failure against adalimumab, infliximab, tofacitinib and other advanced options. East Asian data add efficacy, safety and pharmacokinetic evidence for moderately to severely active disease, including steroid-exposed patients. Remaining questions concern comparative safety and whether these results generalize across populations and treatment histories.
2 papers · 9.5%
-
Others — JAK Inhibition and Safety
JAK inhibition is being assessed across vascular inflammation, platelet activation, autoimmune disease and inflammatory skin conditions. Pan-JAK, JAK1-selective and anti-TNF blockade produce distinct effects on microvascular flow-mediated dilation, while upadacitinib may enhance platelet procoagulant responses in a subset. Clinical reports extend use to refractory checkpoint-inhibitor colitis and non-segmental vitiligo, alongside long-term rheumatoid arthritis comparison with adalimumab. The findings support indication-specific safety assessment rather than a single therapeutic conclusion.
6 papers · 28.6%
Upadacitinib's safety account must include a recurrent semen-discoloration signal
The Chinese multicentre study of difficult-to-treat Crohn's disease and the South Korean case series of men with inflammatory bowel disease both found blue or green semen during upadacitinib treatment, rather than the largely established safety profile implying no distinctive male reproductive signal; the Chinese study also described a suspected paternal reproductive event, although causality was not established 42693782Sep 42325015Jun. Together, these independent observations make semen discoloration a reproducible potential adverse effect that should be actively recognised and monitored rather than treated as an isolated report.
Upadacitinib is repurposed as the JAK1 component of a topical CCR7-targeting smart hydrogel
The pH-responsive hydrogel study in imiquimod-induced psoriasis and DNCB-induced atopic dermatitis mouse models used upadacitinib not as conventional systemic monotherapy but as a locally delivered partner for CCR7-targeting siRNA 42237357Jun. This gives upadacitinib a distinct role as one component of a precision combination-delivery platform designed to co-target immune-cell chemotaxis and inflammatory signaling, extending its use beyond the treatment categories represented by the other papers.
Papers
The 21 papers from the last 6 months that study upadacitinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Atopic Dermatitis Disease Control (7)
- Explorative Correlation of Atopic Dermatitis Control Tool with Minimal Disease Activity Patient-reported Outcomes in Patients Treated with Upadacitinib: A Retrospective Real-world Study. Acta dermato-venereologica · 2 Nov 2026 PMID 42969560
- Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis-A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). Dermatology and therapy · 15 Oct 2026 PMID 42879117
- Characterization of oral microbiome in atopic dermatitis patients treated with dupilumab or upadacitinib. Clinical oral investigations · 6 Oct 2026 PMID 42836883
- Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study. Dermatology and therapy · 1 Oct 2026 PMID 42823606
- Real-World Evidence for the Impact of Minimal Disease Activity on Quality of Life in Atopic Dermatitis: An Interim Analysis of the Prospective, Multicenter, Non-Interventional UP-TAINED Study. Dermatology and therapy · 30 Jul 2026 PMID 42533213
- Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. The Journal of dermatological treatment · 1 Jun 2026 PMID 42223292
- Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). Dermatology and therapy · 29 May 2026 PMID 42213297
Crohn Disease Treatment Outcomes (6)
- Real-world effectiveness and safety of upadacitinib in Crohn's disease up to 18 months. UPITA-Crohn: a multicentre cohort study. Revista espanola de enfermedades digestivas · 12 Nov 2026 PMID 43018399
- Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD). Alimentary pharmacology & therapeutics · 10 Sept 2026 PMID 42720163
- Real-world efficacy and safety of upadacitinib in difficult-to-treat Crohn's disease: a 24-week multicenter study from China. Intestinal research · 4 Sept 2026 PMID 42693782
- Efficacy and Safety Assessment of Upadacitinib for SAPHO Syndrome: A Retrospective Study of 35 Patients. International journal of rheumatic diseases · 28 Aug 2026 PMID 42661505
- Semen Discoloration Following Upadacitinib Therapy in Patients with Inflammatory Bowel Disease. Gut and liver · 22 Jun 2026 PMID 42325015
- Comparative Pharmacokinetics of Two Extended-Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment. Clinical pharmacology in drug development · 29 May 2026 PMID 42212538
Ulcerative Colitis Advanced Therapy (2)
- Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 29 Sept 2026 PMID 42810421
- Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies. Journal of gastroenterology and hepatology · 19 Aug 2026 PMID 42613995
Others — JAK Inhibition and Safety (6)
- Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. Lancet (London, England) · 13 Aug 2026 PMID 42594914
- Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
- Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study. Lupus science & medicine · 7 Jul 2026 PMID 42414040
- Upadacitinib salvage for refractory immune checkpoint inhibitor colitis complicated by cytomegalovirus infection. BMJ case reports · 6 Jul 2026 PMID 42409426
- Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study. RMD open · 24 Jun 2026 PMID 42342288
- A combination therapy strategy: precision co-targeting of CCR7 and JAK1 with a smart hydrogel for inflammatory skin diseases. Journal of nanobiotechnology · 4 Jun 2026 PMID 42237357
By study type
Clinical trials (5)
- Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies. Journal of gastroenterology and hepatology · 19 Aug 2026 PMID 42613995
- Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. Lancet (London, England) · 13 Aug 2026 PMID 42594914
- Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study. RMD open · 24 Jun 2026 PMID 42342288
- Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. The Journal of dermatological treatment · 1 Jun 2026 PMID 42223292
- Comparative Pharmacokinetics of Two Extended-Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment. Clinical pharmacology in drug development · 29 May 2026 PMID 42212538
Observational studies and case reports (5)
- Explorative Correlation of Atopic Dermatitis Control Tool with Minimal Disease Activity Patient-reported Outcomes in Patients Treated with Upadacitinib: A Retrospective Real-world Study. Acta dermato-venereologica · 2 Nov 2026 PMID 42969560
- Efficacy and Safety Assessment of Upadacitinib for SAPHO Syndrome: A Retrospective Study of 35 Patients. International journal of rheumatic diseases · 28 Aug 2026 PMID 42661505
- Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study. Lupus science & medicine · 7 Jul 2026 PMID 42414040
- Upadacitinib salvage for refractory immune checkpoint inhibitor colitis complicated by cytomegalovirus infection. BMJ case reports · 6 Jul 2026 PMID 42409426
- Semen Discoloration Following Upadacitinib Therapy in Patients with Inflammatory Bowel Disease. Gut and liver · 22 Jun 2026 PMID 42325015
Human data, design not indexed (2)
- Characterization of oral microbiome in atopic dermatitis patients treated with dupilumab or upadacitinib. Clinical oral investigations · 6 Oct 2026 PMID 42836883
- Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
Unclassified: not yet indexed with MeSH (9)
- Real-world effectiveness and safety of upadacitinib in Crohn's disease up to 18 months. UPITA-Crohn: a multicentre cohort study. Revista espanola de enfermedades digestivas · 12 Nov 2026 PMID 43018399
- Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis-A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). Dermatology and therapy · 15 Oct 2026 PMID 42879117
- Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study. Dermatology and therapy · 1 Oct 2026 PMID 42823606
- Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 29 Sept 2026 PMID 42810421
- Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD). Alimentary pharmacology & therapeutics · 10 Sept 2026 PMID 42720163
- Real-world efficacy and safety of upadacitinib in difficult-to-treat Crohn's disease: a 24-week multicenter study from China. Intestinal research · 4 Sept 2026 PMID 42693782
- Real-World Evidence for the Impact of Minimal Disease Activity on Quality of Life in Atopic Dermatitis: An Interim Analysis of the Prospective, Multicenter, Non-Interventional UP-TAINED Study. Dermatology and therapy · 30 Jul 2026 PMID 42533213
- A combination therapy strategy: precision co-targeting of CCR7 and JAK1 with a smart hydrogel for inflammatory skin diseases. Journal of nanobiotechnology · 4 Jun 2026 PMID 42237357
- Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). Dermatology and therapy · 29 May 2026 PMID 42213297
Written from 21 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-12 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.